Obesity in Canada surges to one-third of adults, study links spike to pandemic disruptions
have reached alarming levels, with one in three adults now classified as obese, according to a new study published in the Canadian Medical Association Journal (CMAJ). Researchers say the COVID-19
pandemic
played a major role in accelerating this trend.
The study shows that 32.7 percent of Canadian adults, roughly 10.6 million people, were obese in 2023. That's a jump of eight percentage points since 2009, with a sharper rise during the pandemic years.
'The pandemic had such a profound impact on our daily lives, including changes in our eating behaviours and access to healthy foods,' said Laura Anderson, lead author of the study and associate professor at McMaster University.
The research analyzed self-reported
body mass index
(BMI) data from 746,250 Canadians aged 18 or older between 2009 and 2023. Obesity was defined using World Health Organization criteria as a BMI of 30 or higher, or 27.5 for Asian populations.
Before COVID-19, obesity rates in Canada were rising at about 0.5 percentage points per year. During the pandemic, that rate doubled to 1 percent annually. While the study didn't investigate causes directly, experts suggest that mental health and lifestyle disruptions contributed significantly.
Live Events
'There was isolation and depression,' said Dr. Sean Wharton, an internal medicine physician in Ontario. 'People who were living with depression, their depression may have gotten even worse. And that's where we saw people having an increase in their weight.'
The study also found that young adults aged 18 to 39 experienced the highest increases. Severe obesity, defined as a BMI of 40 or more, rose from 2.4 percent in 2009 to nearly 5 percent in 2023. More women were also affected by severe obesity, which researchers say may reflect increased stress and caregiving responsibilities during the pandemic.
While new weight-loss drugs like Wegovy have been approved in Canada, they were not widely available during the study period. Their long-term impact on national obesity rates remains to be seen.
Researchers say the rise in severe obesity is especially concerning due to its links to chronic diseases like diabetes, heart disease, and certain cancers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
37 minutes ago
- New Indian Express
Nine BBMP staffers to be probed over Covid bills
BENGALURU: A Departmental Enquiry (DE) has been ordered against nine BBMP officials in connection with the alleged irregularities in the release of payments related to Covid-19. Following the recommendation from the Justice Michael D Cunha Committee, which was constituted to probe the alleged irregularities in the procurement of Covid-19, notice was issued to 28 officers of the corporation, including engineers, doctors and the officers of the accounts department, seeking an explanation about the purchase of medicines and medical supplies during that period. 19 officers were given a clean chit. The health department, however, ordered an investigation into the remaining officers. 'These are officials in the BBMP health department who failed to give clarity over expenses and bills, and hence the matter was escalated to the BBMP Administration Department. If these officials fail to clarify the doubts, action will be initiated,' said Sirajuddin Madani, Chief Health Officer. Notices have been issued to 15 private companies that supplied materials during the Covid period. The committee has suggested the recovery of Rs 13 crore given to 15 private companies as 'extra'. BBMP Officers and Employees Association president Amruth Raj said it's time the black sheep are shunted out. 'Those involved in dereliction of duty should be suspended and jailed,' he said.
Indian Express
2 hours ago
- Indian Express
Chandigarh to get a new Emergency and Trauma Centre at GMCH-32
Chandigarh's three government hospitals offer both emergency and trauma services, but the rising number of patients has put immense pressure on the current system. At PGI, there are 100 beds each for emergency and trauma care, but on average, 250 to 300 patients are treated daily. In GMSH, Sector 16, there are only 70 beds, yet over 100 patients come in every day. The situation is even more serious at GMCH-32, where there are just 50 emergency beds, but about 120 patients are admitted every day. This shows that the healthcare system is overburdened and handling two to three times more patients than its actual capacity. Due to a lack of space, patients often have to be treated on stretchers or wait in corridors. To enhance healthcare, which will benefit not just Chandigarh, but also surrounding areas, the new Emergency-cum-Trauma Centre at GMCH-32 will finally open doors to patients. Delayed due to Covid, the centre will be inaugurated on July 28. The new block is expected to bring a major transformation in trauma and emergency services. As of now, the combined emergency and trauma capacity in all three hospitals is about 320 beds, but patient load remains two to three times higher on most days. The newly constructed 283-bed Emergency-cum-Trauma Block at GMCH-32 is ready and will further strengthen Chandigarh's healthcare services. This state-of-the-art building includes everything needed in a modern trauma centre, an ICU for critical patients, separate wards for stable cases, isolation units for infectious diseases, and a separate ambulatory care unit for patients who can move around. The effort of the centre is to ensure timely treatment for trauma patients, reduce overload on existing emergency units, improve patient recovery and care, and better coordinate medical staff and resources. To speed up and improve diagnosis, the facility includes digital X-ray, CT scan, MRI, and clinical laboratories. For emergency surgeries, there are two major operation theatres and one minor OT, along with a post-operative ward. A two-level basement parking lot has also been built, which can accommodate 60 cars and 144 two-wheelers. All these facilities are designed to ensure that patients receive the right treatment within the crucial 'golden hour.' The foundation stone of this trauma block was laid in 2019, but the COVID pandemic severely affected the construction process. Work slowed down for nearly two years, and deadlines had to be pushed multiple times. Now, the much-awaited project is complete. Built at a cost of ?42.65 crore, the centre is expected to become fully operational in the first quarter of the upcoming financial year. The inauguration is scheduled for July 28, and GMCH has already started the process of recruiting required faculty and paramedical staff so that services can begin smoothly. It is expected that the new centre will ease the burden on PGI and GMSH-16 and provide better care to emergency patients.
Time of India
4 hours ago
- Time of India
GLP-1 obesity drugs may boost low testosterone
London: GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes , researchers reported in San Francisco at ENDO 2025, the Endocrine Society's annual meeting. Weight loss from lifestyle changes or bariatric surgery is known to boost testosterone levels, but the impact of anti-obesity medications has not been widely investigated, study leader Dr. Shellsea Portillo Canales of SSM Health St. Louis University Hospital in Missouri said in a statement. Portillo Canales and colleagues tracked 110 men with obesity - many also with type 2 diabetes - who were being treated with semaglutide, dulaglutide or tirzepatide, the active ingredients in Novo Nordisk's Wegovy and Ozempic or Eli Lilly's Trulicity, Mounjaro, and Zepbound. The average age was 54. None of the men were receiving other testosterone-boosting medications. During 18 months of treatment, the proportion of men with testosterone levels in the normal range rose from 53% to 77%. Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, strength and red blood cell production. In the current study, the greater the weight loss, the greater the improvement in testosterone levels, the researchers found. While the study cannot prove GLP-1 drugs caused low testosterone levels to normalize, it does show a direct correlation, Portillo Canales noted. INTERMITTENT ACCESS TO GLP-1 DRUGS STILL YIELDS WEIGHT LOSS Popular GLP-1 anti-obesity medications are effective for weight loss even when treatment is inconsistent, new findings suggest. Patients often face challenges in accessing these medications - such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro - due to supply shortages and insurance coverage obstacles, study leader Kaelen Medeiros of privately held weight-loss company Calibrate in New York said in a statement. Medeiros and colleagues looked at how interruptions to GLP-1 medication access over the course of two years impacted weight-loss outcomes in 6,392 clients of Calibrate's online metabolic health program. Along with the drugs, the program also included intensive lifestyle interventions and coaching on diet, exercise, sleep and emotional health. Overall, 72.5% of participants experienced at least one disruption in their GLP-1 treatment and 11.1% had multiple disruptions, Medeiros reported at ENDO 2025. Participants who faced access issues reported a 13.7% weight loss within 12 months and a 14.9% loss within 24 months, on average. Those without treatment interruptions reported a 17% weight loss in 12 months and 20.1% in 24 months, on average. Even those who received no more than four treatments over 12 months also achieved clinically significant weight loss, with more than 10% change in body weight on average. "While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and coaching support," Medeiros said. OSTEOPOROSIS DRUGS CAN BENEFIT HIGH-RISK ELDERLY People who experience a fracture after age 80 might benefit from medications to treat bone deterioration or weakness caused by osteoporosis, researchers reported at the Endocrine Society meeting in San Francisco. Whether to start osteoporosis drugs at that age has been debated for fear that very elderly patients could be more susceptible to the side effects. Researchers at the Cleveland Clinic reviewed medical records on 88,676 patients aged 80 and older who had suffered a fracture due to osteoporosis. Half of them had subsequently been treated with either Merck & Co.'s Fosamax, Roche and GlaxoSmithKline's Boniva, Amgen's Prolia, or Eli Lilly's Evista or Forteo. The others did not receive any osteoporosis drugs. Over the next five years, after accounting for patients' other health conditions, the hospitalization rate was 19% lower and the mortality rate was 15% lower in the group treated with bone-strengthening medications. "The results of our study support the need to enhance the individualized initiation of treatment of osteoporosis, even in people who are older than 80," study leader Dr. Gianina Flocco said in a statement. "Treating people to reduce the burden of osteoporosis complications, like fractures leading to disability or death, would play a significant role in improving health span in the growing older population."
